• 6 months ago

    Gastric Inhibitory Polypeptide and Bone Loss

    There have been few studies of Gastric Inhibitory Polypeptide
    (GIP) and bone in humans. One study found that exogenous administration of GIP did not change serum CTx levels. In contrast, a cohort study found an association between a GIP receptor polymorphism and bone loss. In the Danish Osteoporosis Prevention study, 1686 perimenopausal women were genotyped, BMD was measured at baseline and 10 years later, and fracture data were collected. After 10 years, women with a functional GIP receptor polymorphism Glu354Gln (rs1800437) had significantly lower BMD at the femoral neck and total hip, with an increased risk of nonvertebral fractures. There are fewer studies of GIP and bone in the bariatric surgery population. In a study of obese diabetics who had either RYGB or gastric banding, there was no change in fasting or prandial GIP and no association with bone turnover markers. Visit https://www.creative-peptides.com/product/gastric-inhibitory-polypeptide-and-fragments-18.html to know more.